2020
A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Wu J, Atkinson E, Leichman L, Patel H, Iqbal S, Du K, Bizekis C, Goldberg J, Thomas C, Cohen D, Becker D, Siolas D, Beri N, Oberstein P, Ku G. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2020, 38: 372-372. DOI: 10.1200/jco.2020.38.4_suppl.372.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaClinical CRRadiation therapyPhase I/II studyCarboplatin/paclitaxelEfficacy of nivolumabGrade 2 esophagitisGrade 3/4 AEsGrade 5 toxicityOverall survival benefitPhase II portionSquamous cell carcinomaConcurrent chemoRTManageable toxicityLast dosePrimary endpointII studyUnacceptable toxicityElevated ASTSurvival benefitCell carcinomaChemoRTGrade 3Nivolumab
2018
A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Giuroiu I, Ku G, Leichman L, Du K, Oh P, Levinson B, Iqbal S, Thomas C, Wu J. A phase I/II multi-center study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2018, 36: tps199-tps199. DOI: 10.1200/jco.2018.36.4_suppl.tps199.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaPathologic complete responseOverall survivalClinical CRRadiation therapyMedian progression-free survivalPhase IEfficacy of nivolumabCarboplatin/paclitaxelOverall survival benefitProgression-free survivalKaplan-Meier curvesSquamous cell carcinomaMulti-center studyLast dosePrimary endpointUnacceptable toxicitySurvival benefitComplete responseMeier curvesAbscopal effectCell carcinomaExtensive tumorsEsophageal cancer
2015
Anal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy.
Cooper B, Grew D, Bitterman D, Sanfilippo N, Du K. Anal cancer outcomes in patients treated with intensity modulated versus 3-dimensional chemoradiotherapy. Journal Of Clinical Oncology 2015, 33: 662-662. DOI: 10.1200/jco.2015.33.3_suppl.662.Peer-Reviewed Original ResearchDistant metastasis-free survivalLocal recurrence-free survivalColostomy-free survivalOverall survivalTreatment interruptionLymph nodesTreatment breaksSkin toxicityRadiation therapyThree-year overall survivalAnal cancer outcomesGrowth factor supportRecurrence-free survivalMetastasis-free survivalSquamous cell carcinomaKaplan-Meier survivalConformal radiation therapyRadiation techniquesLog-rank statisticsChi-square testAcute gastrointestinalAcute GIDefinitive chemoradiotherapyIMRT cohortRTOG 0529
2007
Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome
Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Patterns and Levels of Hypoxia in Head and Neck Squamous Cell Carcinomas and Their Relationship to Patient Outcome. International Journal Of Radiation Oncology • Biology • Physics 2007, 69: 1024-1031. PMID: 17967299, PMCID: PMC2737259, DOI: 10.1016/j.ijrobp.2007.04.067.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaPatient outcomesNeck squamous cell tumorsNeck squamous cell carcinomaEvent-free survival timeShorter event-free survival timePositron emission tomographic studiesSquamous cell tumorsLevels of hypoxiaEmission tomographic studiesNodal statusOverall survivalTreatment regimenPrognostic significanceCell tumorsPrimary headMajority of cellsSurvival timeOral cavityHypoxia markersQuantitative immunohistochemistryEF5 bindingSevere hypoxiaPatients